

Date: 18<sup>th</sup> December, 2019

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

Dear Sir/Madam,

**Sub: Alembic Pharmaceuticals Limited announces its joint venture, Aleor Dermaceuticals Ltd., received Establishment Inspection Report (EIR) for its Formulation Facility at Karkhadi**

This is to inform the exchange that Aleor Dermaceuticals Ltd. (Aleor), a 60:40 Joint Venture between Alembic Pharmaceuticals Ltd (Alembic) and Orbicular Pharmaceutical Technologies Pvt. Ltd. (Orbicular), has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for the inspection carried out by them at Aleor's Formulation Facility at Karakhadi, Gujarat, India during the period from 16<sup>th</sup> September, 2019 to 20<sup>th</sup> September, 2019.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

**For Alembic Pharmaceuticals Limited**



**Authorized Signatory**

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229  
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123